UroGen Pharma URGN Lease Liabilities Noncurrent
Lease Liabilities Noncurrent at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept urgn:LeaseLiabilitiesNoncurrent.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's lease liabilities noncurrent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's lease liabilities noncurrent?
- UroGen Pharma (URGN) reported lease liabilities noncurrent of $5.65M in Q1 2026.
- How has UroGen Pharma's lease liabilities noncurrent changed year-over-year?
- UroGen Pharma's lease liabilities noncurrent increased by 98.8% year-over-year, from $2.84M to $5.65M.
- What is the long-term trend for UroGen Pharma's lease liabilities noncurrent?
- Over 2 years (2023 to 2025), UroGen Pharma's lease liabilities noncurrent has grown at a 169.3% compound annual growth rate (CAGR), from $844K to $6.12M.
- What does lease liabilities noncurrent mean?
- This represents the long-term portion of the company's financial obligations arising from operating and finance lease agreements that are due beyond the next twelve months. It reflects the present value of future lease payments for assets essential to the company's business operations. Analyzing this liability is critical for assessing the company's long-term financial leverage and the fixed cost burden associated with its leased facilities and equipment.